Amarin Corp Plc (AMRN)

[ziploc_1]

PFE recently bought Seagen for $43 billion when they could have bought Amarin for about one tenth of that price..It would have fit in well with their other CVD meds...and Vascepa is patent protected in Europe for at least 10 years

Vascepa has a smaller cost to the public than Seagen's cancer drugs, but, with PFE promotion, Vascepa could still have made an important contribution to PFE revenues and earnings at a very reasonable cost to them...during the next few years, as several of their present meds are scheduled to lose their patent protection.